Evidence map›Paper›PMID 38693432›Full record

ArticleScientific reports2024

Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson's disease biomarker panel.

Kuan-Wei Peng, Allison Klotz, Arcan Guven, Unnati Kapadnis, Shobha Ravipaty, Vladimir Tolstikov, Vijetha Vemulapalli, Leonardo O Rodrigues, Hongyan Li, Mark D Kellogg and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Serum L-ornithine-derived polyamines as indicators of Parkinson disease progression.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  2. Article
  3. Article
  4. Polyamine Metabolism in Brain Health and Disease.Neuropharmacology and therapy · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Kuan-Wei PengBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Allison KlotzBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Arcan GuvenBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Unnati KapadnisBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Shobha RavipatyBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Vladimir TolstikovBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Vijetha VemulapalliBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Leonardo O RodriguesBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Hongyan LiBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Mark D KelloggBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Farah KausarDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, 94158, USA.
Linda ReesNeurocrine Biosciences, San Diego, CA, 92130, USA.
Rangaprasad SarangarajanBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Birgitt SchüleDepartment of Pathology, Stanford School of Medicine, Stanford, CA, 94305, USA.
William LangstonDepartment of Pathology, Stanford School of Medicine, Stanford, CA, 94305, USA.
Paula NarainBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Niven R NarainBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Michael A KiebishBPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA. michael.kiebish@bpgbio.com.
Stanford Medicine · USHarvard University · USNeurocrine Biosciences (United States) · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is a progressive neurodegenerative disorder in which loss of dopaminergic neurons in the substantia nigra results in a clinically heterogeneous group with variable motor and non-motor symptoms with a degree of misdiagnosis. Only 3-25% of sporadic Parkinson's patients present with genetic abnormalities that could represent a risk factor, thus environmental, metabolic, and other unknown causes contribute to the pathogenesis of Parkinson's disease, which highlights the critical need for biomarkers. In the present study, we prospectively collected and analyzed plasma samples from 194 Parkinson's disease patients and 197 age-matched non-diseased controls. N-acetyl putrescine (NAP) in combination with sense of smell (B-SIT), depression/anxiety (HADS), and acting out dreams (RBD1Q) clinical measurements demonstrated combined diagnostic utility. NAP was increased by 28% in Parkinsons disease patients and exhibited an AUC of 0.72 as well as an OR of 4.79. The clinical and NAP panel demonstrated an area under the curve, AUC = 0.9 and an OR of 20.4. The assessed diagnostic panel demonstrates combinatorial utility in diagnosing Parkinson's disease, allowing for an integrated interpretation of disease pathophysiology and highlighting the use of multi-tiered panels in neurological disease diagnosis.

Indexed as

BiomarkersParkinson DiseasePutrescineAgedCase-Control StudiesFemaleHumansMaleMiddle AgedProspective StudiesBiomarkersPutrescine

Identifiers

PMID38693432
PMCPMC11063140
OpenAlexW4396589702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.